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Depression is a complex disorder influenced by biological, psychological, and 
environmental factors (Santarelli et al., 2016). Depression is one of the most common forms of 
mental illness worldwide (WHO, 2021), yet the pathogenesis of depression and the mechanism 
of how antidepressants reverse depression remain unclear (Liu et al., 2017).  The symptoms of 
depression are evident to most individuals, but the symptoms’ persistent nature remains a 
mystery to most. The four primary regions of the brain involved in depression are the Prefrontal 
Cortex (PFC), hippocampus, amygdala, and Anterior Cingulate Cortex (ACC) (Hayley et al., 
2013). This review presents the prevailing literature on how antidepressants and Cognitive 
Behavior Therapy (CBT) can reverse depression. More specifically, this paper will examine the 
pathogenesis of depression (chronic stress model of depression); how the combination of 
antidepressants and CBT can help reverse depression (neuroplasticity theory of depression) and 
minimize relapse associated with depression. The neuroplasticity theory of depression is 
supported by evidence of decreased neuroplasticity in the hippocampus and PFC; decreased 
concentration of BDNF; and antidepressants increasing the concentration of BDNF and 
improving neuroplasticity in the hippocampus and PFC (Liu et al., 2017).  The increase in BDNF 
promoting neurogenesis in the hippocampus and PFC also promotes neurogenesis in the 
amygdala, Ventral Tegmental Area (VTA), and Nucleus Accumbens (NAc) (Liu et al., 2017).  
The increase in neurogenesis in the amygdala exasperates depressive-like symptoms and is a 
primary reason for relapse (Hayley et al., 2013).  
The first section of the paper reviews the stress model of depression and the disruption in 
structural neuroplasticity (Liu et al., 2017). The second section entails the neuroplasticity theory 




the concentration of neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF) 
and promoting positive neuroplasticity in the PFC and hippocampus (Liu et al., 2017).   The third 
section examines the efficacy of combining antidepressants and CBT, and how CBT can help 
reduce relapses in depression caused by hyperactivity of the amygdala (Arnau-Soler et al., 2016). 
Finally, the last section presents recommendations for future studies, such as advancing the 
correlation between genetics and depression; the molecular mechanisms involved in depression; 




































According to the American Psychiatric Association (APA), "depression is a medical 
illness that negatively affects how you feel, the way you think and how you act" (American 
Psychiatric Association [APA], 2013). Depression is a complex disorder influenced by 
biological, psychological, and environmental factors (Santarelli et al., 2016). Depression is one 
of the most common forms of mental illness worldwide (WHO, 2016), yet the pathogenesis of 
depression and the mechanism of how antidepressants reverse depression are still unclear (Liu et 
al., 2017).  Historically, the medical community has propagated the monoamine (serotonin  
[5-HT], norepinephrine [NE], and dopamine [DA]) hypothesis as the prevailing explanation of 
the pathogenesis of depression and antidepressants' targets of monoamine receptors and 
transporters.  
The monoamine hypothesis incompletely postulates that depression is due to a 5-HT, NE, 
or DA deficiency. Therefore, antidepressants resolve the deficiency by inhibiting the 
neurotransmitters' reuptake in the synaptic cleft or other methods of limiting their clearance, thus 
alleviating depressive symptoms. An increase in 5-HT, NE, or DA in the synaptic cleft does not 
efficiently explain the efficacy of antidepressants (Liu et al., 2017).  There are three reasons why 
the monoamine hypothesis fails to explain the efficacy of antidepressants. First, the delayed 
onset (~2 weeks) of the effects from antidepressants is inconsistent with the more immediate 
increase in 5-HT concentration in the synaptic cleft. Second, lowering the concentration of 5-HT 
in the synaptic cleft via acute tryptophan depletion or serotonin transporter (SERT) enhancer has 
failed to induce depression in healthy adults. Third, researchers have shown genetic variants 




reduction in depression, and variants associated with a decrease in SERT function (s allele of 5-
HTTLPR) are correlated with an increase in depression (Liu et al., 2017).     
Newer paradigms have emerged attempting to identify and explain what is referred to as 
the "final common pathway" (Liu et al., 2017), which underlies the pathogenesis or vulnerability 
to depression, and antidepressants' efficacious effects in reversing or repairing the alteration of 
this "final common pathway." Researchers have made great strides in correlating the 
neurobiological effects of stress on the brain leading to depression; and have provided insights 
into the "final common pathway" of depression and its reversal by antidepressants and Cognitive 
Behavior Therapy (CBT) (Liu et al., 2017). 
 
BACKGROUND 
Pathogenesis of Depression (Stress Model of Depression) 
 The stress model of depression describes the relationship between stress and depression, 
exploring how the gene X environment interaction influences the hypothalamic-pituitary-adrenal 
(HPA) axis in creating negative neuroplasticity (Liu et al., 2017). Neuroplasticity refers to the 
neural system's ability to adapt to stimuli and respond proficiently to future stimuli by forming 
and reorganizing synaptic connections (Liu et al., 2017). Gene X environment refers to how 
different genotypes are affected by the same environment, thus influencing their vulnerability to 
disease (Lopizzo et al., 2017). Depression is a multifactorial and polygenic disorder where 
multiple and partially overlapping sets of genes interact with each other and with the 
environment (Lopizzo et al., 2017).  The interplay between environmental factors (such as a 
stressful life event [SLE]) and an individual's genetics mediating and adapting to stress can 




is the initiator and catalyst in promoting negative neuroplasticity. Negative neuroplasticity occurs 
when an individual with a maladaptive stress response to an SLE triggers a cascade of neurotoxic 
events. The dysregulation of the HPA axis creates a hypercortisolemic environment that exerts 
neurotoxic effects on hippocampal neurons through the glucocorticoid receptors (GR), resulting 
in decreased neurogenesis, synaptogenesis, and dendritic spines, and an increase in apoptosis of 
neurons (Liu et al., 2017).  Furthermore, chronic stress increases glutamate release in the 
hippocampus and prefrontal cortex (PFC) and decreases serotonin and dopamine 
neurotransmission. Stress also influences the decrease in neuronal cell proliferation and promotes 
apoptosis of glial cells responsible for the clearance of glutamate in the brain. In a vicious cycle, 
chronic stress continues to exasperate the ill-adaptive stress response promoting negative 
neuroplasticity in the brain (Liu et al., 2017).  The pathogenesis of depression can be assessed 
through the lens of the chronic stress model of depression and an examination into how 
antidepressants and CBT can reverse negative neuroplasticity caused by stress.  
Neuroplasticity of Depression and Antidepressants 
Neuroplasticity has a morphological and a functional component. Furthermore, within the 
scope of neuroplasticity exists metaplasticity, defined as "activity-dependent and persistent 
change in neural state that shapes the direction, duration, or magnitude of future synaptic 
change" (Liu et al., 2017).  Metaplasticity is sensitive to both positive environmental cues and 
negative environmental cues (such as stress).  
According to the neuroplasticity theory of depression (Liu et al., 2017), antidepressants 
can reverse the maladaptive circuitry by: (a) stimulation of postsynaptic monoamine receptors; 
(b) regulation of presynaptic glutamate, specifically in the PFC; (c) stimulation of AMPA and 




Factor (BDNF); (d) potentiation of synaptogenesis in the hippocampus, suppressed by stress; and 
(e) antidepressant may also improve neurogenesis in the hippocampus through activation of the 
5-HT1A receptor (Liu et al., 2017).  The neuroplasticity theory of depression is supported by 
evidence of decreased neuroplasticity in the hippocampus and PFC; decreased concentration of 
BDNF; and antidepressants increasing the concentration of BDNF and improving neuroplasticity 
in the hippocampus and PFC (Liu et al., 2017).  The increase in BDNF promoting neurogenesis 
in the hippocampus and PFC also promotes neurogenesis in the amygdala, Ventral Tegmental 
Area (VTA), and Nucleus Accumbens (NAc) (Liu et al., 2017).  The increase in neurogenesis in 
the amygdala exasperates depressive-like symptoms and is a primary reason for relapse (Hayley 
et al., 2013).  In most individuals with depression, CBT can help counter the amygdala's elevated 
activation if antidepressants alone are not sufficient (Arnau-Soler et al., 2016).  
Neuroplasticity and Cognitive Behavior Therapy (CBT) 
CBT is a form of psychological treatment that challenges and modifies beliefs, behaviors, 
and feelings (Corey, 2016). CBT is rooted in principles denoted by a collaborative relationship; a 
focus on the present; an active and directive stance by the therapist; a psychoeducational 
approach; and a focus on cognition influencing psychological distress. The goal of CBT is to 
help individuals recognize negative beliefs and change cognitive perceptions of their 
environment. A function of the PFC is to regulate cognitive control by processing stimuli and 
responding appropriately. Cognitive dysfunction observed in an individual with depression is 
predominantly due to hypoconnectivity of the frontoparietal networks leading to deficits in 
processing stimuli, reduced attention, concentration, and executive function (Andrade et al., 
2010). CBT can improve network connectivity seen in depression by increasing the functional 




improve an individual's mood, creating a positive effect by increasing activity in the dorsolateral 
and dorsomedial PFC, and minimizing activity in the amygdala (Uscinska et al., 2019). 
Antidepressants and CBT 
Depression is a complex disorder that requires a treatment plan specific to each 
individual (Roiser et al., 2012). Antidepressants are pharmacologically beneficial but have a 
ceiling of efficacy. Antidepressant-induced neuroplasticity will not permanently reverse the 
negative neuroplasticity in the PFC and hippocampus caused by stress. The vulnerability and 
maladaptive response to an SLE will continue to persist. Stress is a constant enabler, and thus 
individuals living with depression may need continuous maintenance of antidepressant therapy 
(Andrade et al., 2010). Therefore, the combination of an antidepressant and CBT is the best 
approach to treating depression. Both antidepressants and CBT are efficacious in treating 
depression, but their therapeutic effects are achieved in different ways. Antidepressants' effects 
(Uscinska et al., 2019) consist of a "bottom-up" approach; in comparison, CBT's effects consist 
of a "top-down" approach. Importantly, there is a favorable window at the start of antidepressant 
therapy for imprinting healthy cognitions and behaviors, establishing healthy neurocircuitry. 
Implementing treatment outside of this therapeutic window will increase the chance of 
antidepressant refractoriness (Andrade et al., 2010).  Additionally, an individual's environment, 











A comprehensive literature search was performed using PubMed and Google Scholar 
databases to retrieve original articles that evaluated research relating to the topic of 
neuroplasticity of depression and how antidepressants and CBT reverse the effects of depression. 
The literature analysis included a review of published literature from diverse disciplines (Clinical 
Neurology, Psychology, Neuropharmacology, Neurophysiology, and Radiology) and a range of 
interdisciplinary research and clinical method strategies (molecular and genetics, 
imaging/functional study modalities, and clinical research). More specifically, the published 





Pathogenesis of Depression 
 
Newer paradigms have emerged attempting to identify and explain what is referred to as 
the "final common pathway" (Liu et al., 2017), which underlies the pathogenesis or vulnerability 
to depression, and antidepressants' efficacious effects in reversing or repairing the alteration of 
this "final common pathway." It is well understood that a primary symptom of depression is a 
loss of interest (anhedonia) (Stone et al. 2008). Anhedonia in depression is the product of a "final 
common pathway" or common final neural state. The neural network that mediates positively 
motivated behavior involves the interplay between the dorsal (positive motivation) brain regions 
(PFC, parietal and temporal cortices, limbic, hypothalamus [lateral], and thalamus), that regulate 
the ventral (stress regions) brain regions (amygdala, subgenual anterior cingulate cortex 




terminalis [BNST]) (Stone et al. 2008). The Mayberg model, via neuroimaging studies, support 
the premise of an interplay between the dorsal (positive motivation regions) and ventral (stress 
regions) in the development of the symptoms of depression (Stone et al. 2008). The Mayberg 
model states that a shift in neuronal activity favors the ventral (stress) regions in individuals with 
depression (Stone et al. 2008). 
What is the pathogenesis of depression? Short answer: depression is a multifactorial and 
polygenic disorder where multiple and partially overlapping sets of genes interact with each 
other and the environment (Lopizzo et al., 2017). Current research postulates multiple factors 
such as HPA axis dysfunctions, neuroimmune responses, neurodegenerative alterations, 
circadian rhythms, genetics, and epigenetics play a role in the pathology of depression (Massart 
et al., 2012). The common denominators underlying all of the mentioned etiologies are stress and 
genetics. All of the above factors play a role in the complexities of depression, but stress is 
central in the pathogenesis of depression. This review's focus is not to discuss all current 
research (theories) on the pathogenesis of depression but to explore one of the primary 
contributors, namely the stress (chronic) model of depression. Of note, chronic stress is defined 
by the HPA axis response and other systems that participate in physiological adaptation (e.g., 
autonomic nervous system, immune system, brain behavioral prioritization, among others) 
(Herman et al., 2016). 
The various biological systems encompassing all organisms can maintain homeostasis or 
a dynamic equilibrium (de Kloet et al., 2005). The dynamic equilibrium can be disturbed by 
physiological and psychological events known as 'stressors' (de Kloet et al., 2005). In 
accordance, organisms are constantly monitoring and appraising stressors toward the pursuit of 




previous cognitive experiences and procuring an appropriate response. If a reference point does 
not exist, the response increases alertness, vigilance, and cognitive processing. The interplay 
between incoming sensory information and the appraisal process involves the hippocampus, 
PFC, and amygdala (de Kloet et al., 2005).  
Stress is divided into two responses, acute stress response and chronic stress response (de 
Kloet et al., 2005). The general adaptive syndrome (GAS) illustrates the model of acute stress, 
consisting of three stages: alarm, resistance, and exhaustion. The alarm stage consists of 
perceiving a threat or stressor; the resistance stage consists of a physiological response, regulated 
by the sympathetic nervous system; and the exhaustion stage, which consists of depleting bodily 
resources due to prolonged stress when appropriate coping mechanisms fail to contain the 
stressor. The normal stress response is termed "allostasis," entailing an effective coping 
mechanism to a stressful event that incudes rapid activation and proper termination. If a 
maladaptive or an inadequate stress response occurs, it is referred to as an allostatic load and is 
deemed chronic (de Kloet et al., 2005). It is understood that stress influences neurogenesis; 
reciprocally, neurogenesis influences the stress response (Egeland et al., 2015). This review 
focuses on the latter, chronic stress and its pathology.  
Hypothalamic-Pituitary-Adrenocortical Axis (HPA) Axis 
 
When a stressful event is detected by the brain via limbic pathways and ascending brain 
pathways from sensory and visceral stimuli, the adapted physiological response functions in two 
modes: fast and slow (de Kloet et al., 2005). The fast mode begins with the hypothalamic release 
of Corticotropin-Releasing Hormone (CRH) and activation of the sympathetic, "fight or flight" 
response. The sympathetic response (secretion of CRH) is regulated by the CRH1 receptor 




vasopressin (AVP) from the paraventricular nucleus (PVN) of the hypothalamus by parvocellular 
neurons occurs. The parvocellular neurons secrete CRH and vasopressin and activate pro-
opiomelanocortin (POMC) synthesis in the anterior pituitary, leading to secretion of 
adrenocorticotropin hormone (ACTH). ACTH stimulates the release of corticosteroids (cortisol) 
in the adrenal cortex. Corticosteroids circulate throughout the body for the function of stress, 
recovery, and adaptation. The receptor system encompassing MR (mineralocorticoid receptor) 
and GR (glucocorticoid receptor) binds to the same corticosteroid, cortisol. The release of 
corticosteroids by the adrenal cortex is involved in both modes of stress response and is 
regulated by MR and GR. MR and GR are complementary to each other in the management of 
the stress response. MR predominately is tasked with predictability, appraisal and risk 
management, reactivity, flexibility, and the onset of the stress reaction. GR functions are 
controllability, memory storage, adaptation, and terminating the stress reaction. The binary 
receptor system coordinates an efficient and effective stress response (de kloet, 2013). The HPA 
axis is regulated by a negative-feedback loop utilizing cortisol in the regulation of CRH and 
AVP secretion by activating GRs in the hippocampus and paraventricular nucleus neurons in the 
hypothalamus.  
The hyperactivity of the HPA axis is due to the dysregulation of GRs. The hippocampus 
and its inhibitory regulation of the HPA axis are compromised, in turn, increasing the circulating 
corticosteroid levels, leading to more detrimental hippocampal dysfunction (Massart et al., 
2012). A hypercortisolemic environment creates a vicious cycle due to chronic stress (Holsboer, 
2000). However, the corticosteroid signaling cascade is complex and involves various 
transcription factors, chaperones, proteins, and regulatory mechanisms that mediate MR and GR 




imbalance in the MR:GR ratio has been detected in depressed patients (de Kloet et al., 2005). 
Research (Vose et al., 2017) has shown that chronic stress in rodents can change the amount of 
corticosterone (cortisol equivalent) and ACTH released and altering MR and GR's sensitivity in 
the hippocampus, PFC, and other brain areas.  
Genetic Considerations 
The combination of a stressful life event (SLE) and genetic susceptibility can have a 
detrimental impact on the MR and GR signaling mechanism, thus creating a vulnerable 
phenotype (de Kloet et al., 2005). An individual's vulnerability to depression is defined at three 
levels: clinical phenotype (psychological - emotional reactivity); functional phenotype 
(physiological – neuroendocrine reactivity); and genotype (genetics – i.e., polymorphisms in GR 
gene). Particular genetic backgrounds have been shown to increase susceptibility to depression, 
such as polymorphisms in the GR or FKBP5 gene, both implicated in HPA axis hyperactivity. 
Conversely, particular genetic backgrounds have been shown to increase resiliency in developing 
depression, such as a polymorphism in the ER22/23 EK allele of the GR gene. An individual 
with the resiliency polymorphism exhibits healthier cognitive function than the general 
population and better treatment outcomes if they develop depression. Other polymorphisms of 
the GR gene have also been implicated in dysfunctional regulation of HPA response to stress (de 
Kloet et al., 2005). 
In 2020, Belzeaux et al. published a study identifying the G protein-coupled receptor 
(GPR56) encoded by ADGRG1 gene, as a possible biomarker for depression and antidepressant 
efficacy (Belzeaux et al., 2020). The study indicated downregulation of GPR56 in the PFC is 
correlated to depressive behavior. Furthermore, chronic stress induces the downregulation of 




Chronic Stress Effects on Neuroplasticity 
Hippocampus  
Prolonged corticosteroid exposure has been implicated in negative neuroplasticity in the 
hippocampus, causing a reduction in neurogenesis and impairment of synaptic plasticity 
Pittenger et al., 2008). The morphological changes caused by chronic stress include atrophy of 
apical dendritic spines and branches of the pyramidal neurons in the CA3 (cornu ammonis) and 
suppression of new granule neurons in the dentate gyrus (DG) (Pittenger et al., 2008). These 
long-term effects of chronic corticosteroid elevation in the hippocampus have been hypothesized 
to occur via epigenetic mechanisms (i.e., DNA methylation and histone modification) in the 
HPA axis (Pittenger et al., 2008). Elevated levels of corticosteroids target genes that encode 
structural proteins changing dendritic morphology, in turn altering the length of the tree, as well 
as alterations in the glutamate-induced voltage shift in the soma (de Kloet et al., 2005). 
Glutamate, the primary neurotransmitter in the brain, is highly influenced by overactive 
corticosteroid levels, increasing NMDA (glutamate) receptor activity leading to dysfunction in 
glutamate signaling and potentially leading to excitotoxicity in the cells (de Kloet et al., 2005).   
Another hippocampal area affected by chronic stress and elevated corticosteroid levels is 
the dentate subgranular zone and the reduced activity in the proliferation of its progenitor cells. 
Chronically elevated corticosteroid levels hinder proliferation in the dentate subgranular zone, 
but a partial reversal is possible with treatment (Pittenger et al., 2008).   
Long-term Potentiation and Long-term Depression in the Hippocampus 
Long-term potentiation (LTP) in the hippocampus is the persistent stimulation of afferent 
fibers leading to synaptic plasticity via NMDA (glutamate) receptors and the induction of 




of LTP and functions to prevent the saturation of hippocampal synapses by decreasing synaptic 
strength (NMDA receptors) using low-frequency stimulation of afferent fibers. In depression, the 
imbalance between LTP and LTD is tipped in favor of LTD (Pittenger et al., 2008). Elevated 
corticosteroid levels impair hippocampal neurogenesis. Low corticosteroid levels amplify long-
term potentiation (LTP) due to preferential activation of MRs in the hippocampus. Conversely, 
high corticosteroid levels mitigate LTP due to saturated MRs in the hippocampus, leading to 
activation of GRs (de Kloet et al., 2005).   
Prefrontal Cortex  
Chronic stress affects the PFC, specifically medial PFC (mPFC), similarly to the 
hippocampus. Chronic stress reduces the induction of LTP within the PFC and induces atrophy 
of the apical dendrites of pyramidal cells in the mPFC (Pittenger et al., 2008). Chronic stress 
minimizes the excitatory pathways projecting to the PFC, leading to PFC hypoactivity in 
depression. Conversely, in depression, the amygdala is hypertrophic and hyperactive, thus 
enhancing the projections from the ventromedial PFC (vmPFC) to the amygdala (Pittenger et al., 
2008). The projections between the PFC, hippocampus, and amygdala are complex but described 
here in simple terms: chronic stress minimizes LTP induction in the hippocampal-PFC and 
basolateral amygdala-PFC synapses, but the connection, going from PFC to the basolateral 
amygdala, experiences an upregulation in LTP induction (Vose et al., 2017). The mPFC is 
compromised in depression, thus decreasing its ability to effectively communicate with the 
hippocampus and mediate adverse behavior (Kim et al., 2015). 
Amygdala: Stress-Induced Hypertrophy  
Chronic stress enhances hypertrophy in the amygdala, possibly due to increased 




2008). The sites of neurogenesis in the amygdala are regionally specific. According to Pittenger 
et al. (2008), “Stress induces increased neuroplasticity (synaptogenesis, elongation of dendritic 
spines, and dendritic spine density) in the basolateral amygdala principal cells and in the bed 
nucleus of the stria terminalis (BNST), a projected target of the amygdala” (Pittenger et al., 
2008).  Increased LTP in the basolateral amygdala leads to increased fear learning and anxiety. 
Interestingly, in the central amygdala, chronic stress has delayed neurogenesis (induction of LTP 
and dendritic arborization), which has been an area of focus for reversing the effects in the 
basolateral amygdala and hippocampus (Vose et al., 2017). The lateral amygdala (LA) is also 
implicated in the stress-induced increase in LTP (Suvrathan et al., 2014). Chronic stress 
promotes greater neural excitability and reduced GABAergic regulation; the increased 
excitability results in the upregulation of NMDARs (glutamate) and an increase in LTP 
(Suvrathan et al., 2014).   
Contributions of Glutamate to Neuronal Atrophy After Stress  
It is understood that hyperactive glutamate release can cause excitotoxicity and 
potentially lead to cell death (Sanacora et al., 2012).  Glutamate, the brain's primary 
neurotransmitter, far outnumbers other neurotransmitters in the brain, except for GABA 
(Sanacora et al., 2012). Glutamatergic synapses in the brain are tripartite (presynaptic, 
postsynaptic, astrocytic glia cells). Astrocytes are necessary for the reuptake of glutamate in the 
synaptic cleft. Astrocytic glial cell dysfunction (low ratio of glia to neurons) plays a role in the 
pathology of depression (Vose et al., 2017).  
The primary brain structures associated with depression, such as PFC, hippocampus, and 
amygdala, communicate via glutamatergic signaling (Vose et al., 2017). Acute stress increases 




in the CA1 of the hippocampus. Chronic stress increases extracellular glutamate in the CA3 
region of the hippocampus. Chronic stress-induced increases in the extra-synaptic sites disturb 
the balance between synaptic and extra-synaptic NMDA (glutamate) receptors creating 
excitotoxicity and neurodegeneration (Pittenger et al., 2008). The effects of chronic stress on 
reducing postsynaptic ionotropic glutamate receptors (GluN2B and GluA2/GluA3) in the PFC 
have been proposed as a mechanism underlying the dysregulation of fear extinction (Sanacora et 
al., 2012).       
Glial Cells (Astrocytes) 
Glial cells in the brain, specifically astrocytes, have the role of regulating K+ and 
glutamate in determining excitability levels of neurons and neurotransmitter metabolism (Rial et 
al., 2015).  Glial cells regulate the synaptic levels of glutamate that augment NMDA and AMPA 
receptors' density on the postsynaptic membrane influencing synaptic plasticity (Rial et al., 
2015). Glial cells’ regulatory mechanism involves Excitatory Amino Acid Transporters 1 and 2 
(EAAT1 and EAAT2), which are astroglia glutamate transporters that function to prevent excess 
excitability and potential spillover into the extra-synaptic space, thus mitigating glutamate 
excitotoxicity (Sanacora et al., 2012). Chronic stress has been shown to decrease the proliferation 
of glial progenitor cells (Sanacora et al., 2012). One of the glial cells' roles is in 
neurotransmitters' metabolism, specifically, converting glutamate into glutamine, a precursor for 
GABA (inhibitory neurotransmitter in the brain). GABA plays a significant role in the continual 
maintenance of neuronal homeostasis (Sanacora et al., 2012). In depression, there is a 
dysregulation in the frontolimbic region where astrocytes have lost the ability to regulate 
synaptic levels of K+ and clearance of extracellular glutamate, resulting in increased excitability 






Neuroplasticity of Depression and Antidepressants (Structural and Functional Changes) 
As previously defined in the background section, neuroplasticity refers to the neural 
system's ability to adapt to stimuli and respond proficiently to future stimuli by forming and 
reorganizing synaptic connections (Liu et al., 2017). Neuroplasticity has a morphological and 
functional component. Furthermore, within the scope of neuroplasticity exists metaplasticity, 
defined as "activity-dependent and persistent change in neural state that shapes the direction, 
duration, or magnitude of future synaptic change" (Liu et al., 2017).  Metaplasticity is sensitive 
to both positive environmental cues and negative environmental cues (such as stress). 
Researchers have shown that the brain is more plastic than previously thought. Furthermore, the 
brain contains stem cells that can differentiate into neuronal or glial cells, thus contributing to the 
neuroplasticity of pharmacotherapy (antidepressants) and psychotherapy (CBT) treatments 
(Higgins et al., 2019). 
Neuroplasticity of Antidepressants – Early Changes  
 
The initial neuroplasticity changes are facilitated by glutamate binding to the 
postsynaptic NMDAR (ionotropic glutamate receptor). The NMDAR cascade, in this case, 
activates lipid-signaling pathways (arachidonic acid, platelet-activating factors, prostanoid, 
among others) in a positive-feedback regulation. NMDAR activation also initiates calcium 
calmodulin-dependent kinase II (CaMKII) and increases AMPARs (ionotropic glutamate 
receptor). The glutamatergic cascade results in long-term potentiation (LTP) and synaptic 








Neuroplasticity of Antidepressants – Long-Term Changes  
 
“Long-term changes involve the induction of neurotrophic factors such as brain-derived 
neurotrophic factor (BDNF) that act on tyrosine kinase (Trk) receptors to activate intracellular 
cascades such as cAMP-PKA, CaMKII, mitogen-activated intracellular kinase (MAPK), among 
others” (Andrade et al., 2010). These signaling molecules, in turn, activate various transcription 
factors, most importantly, cAMP response element-binding protein (CREB). CREB, in turn, 
activates the synthesis of proteins and enzymes (BDNF, VEGF, etc.) involved in the 
cytoarchitecture of neuroplasticity (Andrade et al., 2010). The end products of the intracellular 
signaling cascades are neurogenesis (synaptogenesis, dendritic branching, etc.) and increased 
glial cells in the hippocampus (predominantly, dentate gyrus), PFC, and amygdala (Andrade et 
al., 2010) - consistent with the timeline of antidepressants. 
Antidepressants Can Reverse the Maladaptive Circuitry By: 
 
1. Stimulation of postsynaptic monoamine receptors 
Antidepressants can promote positive neuroplasticity by stimulation through postsynaptic 
monoamine receptors. Generally, G-protein coupled receptors (GPCR) initiate an intracellular 
cascade consisting of the activation of adenylate cyclase (AC), which catalyzes ATP to cyclic 
adenosine monophosphate (cAMP), which activates cAMP response-element binding protein 
(CREB) via protein kinase A (PKA) (Carlezon et al., 2005). CREB is the transcription factor 
responsible for gene expression of many of the proteins (BDNF, GluR1, among others) involved 
in neurogenesis in the hippocampus and other areas in the brain. The atrophy in the hippocampus 
and PFC created by chronic stress can be reversed by increasing neurogenesis in these areas; one 






CREB is expressed in all cells of the brain. CREB resides in the nucleus functioning as a 
transcription factor, specifically stimulus-transcription coupling (cell membrane events into gene 
expression). CREB is predominantly responsible for the expression of most neuronal proteins, 
thus wielding tremendous influence over individual neurons and neuronal circuits (Carlezon et 
al., 2005). In the hippocampus, the increase in CREB activity plays an instrumental role in the 
efficacy of antidepressants (selective serotonin-reuptake inhibitors [SSRI] and Serotonin-
norepinephrine reuptake inhibitors [SNRI]). CREB promotes the expression of one of its target 
genes, BDNF. BDNF, a growth factor, stimulates neurogenesis and dendritic arborization. 
Hippocampal neurogenesis helps regenerate the negative neuroplasticity caused by chronic stress 
and restores normal mood (Carlezon et al., 2005). Such processes are aligned with the timeline of 
antidepressants' efficacy (Carlezon et al., 2005).  
With respect to dynamic equilibrium, high expression of CREB has its disadvantages. 
Increases in CREB in the hippocampus produce antidepressant effects. Conversely, a similar 
increase in CREB in the nucleus accumbens (NAc) produces depressive-like symptoms due to 
increased dynorphins and stimulation of K opioid receptors. Therefore, CREB can have adaptive 
and maladaptive effects depending on the brain structure. Thus, extreme increases or decreases 
in CREB activity can be detrimental. Furthermore, standalone CREB therapeutics as 
antidepressants have had difficulty gaining traction because of the brain's global expression 
(Carlezon et al., 2005).   
2. Regulation of presynaptic glutamate, specifically in the PFC 
Antidepressants regulate presynaptic glutamate secretion by a mechanism illustrated in a 




period, which reduced depolarization-evoked release of glutamate. Chronic treatment of 
antidepressants creates an adaption that changed the protein-protein interactions involved in the 
presynaptic SNARE (soluble N-ethylmaleimide-sensitive fusion protein attachment protein 
receptor) protein complex (formed by synaptobrevin-2, syntaxin-1, and SNAP-25) that regulates 
fusion of presynaptic vesicles with the presynaptic membrane (Sanacora et al., 2012). This 
process (Sanacora et al., 2012) entails the phosphorylation of CaMKII (high concentration at 
synapses), resulting in the reduced binding of syntaxin-1 to CaMKII and increased binding to 
Munc-18 (protein in synaptic vesicles fusion and exocytosis). In turn, syntaxin-1 and the SNARE 
complex interaction are reduced, resulting in a decrease in the depolarization-evoked release of 
glutamate (Sanacora et al., 2012). The reduction in glutamate release helps reduce neurotoxic 
effects caused by glutamate excitotoxicity, thus promoting an environment for neurogenesis, 
synaptogenesis, and neurocircuitry (Liu et al., 2017). 
3. Stimulation of AMPA and inactivation of NMDA receptors, thus enhancing 
expression of Brain-Derived Neurotrophic Factor (BDNF) 
BDNF    
 
Brain-derived neurotrophic factor (BDNF) is broadly expressed throughout the brain regions 
but with higher densities in the dentate gyrus (DG) and the subventricular zone (SVN) structures 
(Miao et al., 2020). BDNF's role is to regulate neurogenesis and neuronal maintenance. BDNF 
has two primary target receptors, tropomyosin receptor kinase B (TrkB) and p75 receptor 
(p75NTR). BDNF is secreted by neuronal cells, crosses the blood-brain barrier (BBB), and is 
regulated by CREB, as previously mentioned. Research (Miranda et al., 2019) has shown that 
BDNF contributes to regulating the remodeling of 5-HT neuronal terminals in the cortical 




(sBDNF) is lower in individuals with depression. One of the antidepressants' effects is to 
increase BDNF expression in the hippocampus, promoting neurogenesis and dendritic 
arborization (Carlezon et al., 2005).    
BDNF polymorphisms (such as val66met) have been implicated in decreased BDNF leading 
to reduced hippocampal functioning (Pittenger et al., 2007). Epigenetic modulations such as 
DNA methylation and histone modification have also contributed to the inhibition of various 
Bdnf gene variants and their expression, leading to the reduction of BDNF (Miao et al., 2020). 
For example, chronic stress has been implicated in the DNA methylation at the Bdnf exon IV 
promoter region, thus reducing BDNF expression in the hippocampus (Miao et al., 2020). 
Stimulation of AMPA and inactivation of NMDA receptors 
 
Antidepressants such as Ketamine (non-competitive NMDA antagonist) exhibit a 
different therapeutic mechanism of action than other antidepressants (monoaminergic 
antidepressants). Ketamine increases the release of presynaptic glutamate (Du et al., 2006). The 
increased glutamate release preferentially favors AMPARs over NMDARs due to Ketamine's 
blockade of NMDARs (Du et al., 2006). In turn, this results in upregulation of AMPARs (GluR1, 
among others) and an increase in intracellular signaling cascades that promotes increased 
expression of BDNF and increased exocytosis of BDNF by increasing Ca2+ in the cytoplasm. 
The extracellular BDNF will stimulate its membrane receptor TrkB resulting in increased gene 
expression and increased neuroplasticity (Liu et al., 2017). Ketamine's effects are experienced 
faster than monoaminergic antidepressants' (~2 weeks) effects because Ketamine only requires 
protein translation but not transcription resulting in a faster synthesis of BDNF, thus increasing 
neurogenesis. The translation of BDNF via ketamine mechanism of action, is due to the 




inhibition of NMDAR, which leads to inhibition of eEF2K and dephosphorylation of eEF2 and 
increasing translation and BDNF synthesis (Monteggia et al., 2103). Monoaminergic 
antidepressants, indirectly increase AMPAR expression but after a series of downstream 
signaling cascades at a more gradual rate (Monteggia et al., 2103). 
Although the increase in presynaptic glutamate release yielding antidepressant effects may 
seem contradictory at first, the glutamate receptor family is complex and diverse. Furthermore, 
an alternative explanation of whether an increase in glutamate is "good" or "bad" is referred to as 
the "NMDAR paradox" (Hardingham et al., 2010). The NMDAR paradox states that it is the 
location of NMDARs that determines a neuroprotective or neurotoxic glutamatergic signal. 
Accordingly, synaptic NMDARs exhibit neuroprotective behavior in contrast to extra-synaptic 
NMDARs that exhibit neurotoxic behavior (Hardingham et al., 2010). Furthermore, this concept 
illustrates that synaptic Ca2+ overload is not the predominant reason for excitotoxicity, but 
instead, it is the Ca2+ overflow to the NMDARs in the extra-synaptic region that is implicated in 
neurotoxicity (Hardingham et al., 2010).   
4. Potentiation of synaptogenesis in the hippocampus, suppressed by stress 
 
Antidepressants have been shown to increase LTP in the dentate gyrus by increased 
stimulation of the perforant pathway to granule cells. One study stated, "SSRI (fluoxetine) 
administration increases baseline field potentials in the dentate gyrus" (Pittenger et al., 2007). 
The increase in neuroplasticity in the dentate gyrus may be due to newborn granule cells that 
exhibit greater plasticity potential. Furthermore, Hayley et al. (2013) state that approximately a 
third of hippocampal neurons can be exchanged during a lifespan (Hayley et al., 2013). Also, 




LTD in the CA1 region of the hippocampus (Pittenger et al., 2007). The result is an increase in 
neurogenesis and synaptic connectivity via LTP processes (Liu et al., 2017). 
5. Antidepressant may also improve neurogenesis in the hippocampus through 
activation of the 5-HT1A receptor   
 
5-HT1A receptors play an essential role in the mechanism of action of antidepressants. 5-HT 
neurons are predominantly located in two brain regions: raphe nuclei (presynaptic auto-
receptors) and postsynaptic neurons of 5-HT nerve terminals in the cortico-limbic regions. 5-
HT1A receptors are located in the somatodendritic region and respond to local serotonin by 
increasing potassium conductance; hyperpolarizing the neuronal membrane; and inhibiting 
serotonergic firing pyramidal neurons in the hippocampus and cortex regions. This mechanism 
helps to desensitize the 5-HT1A receptor first and then to await recovery. The postsynaptic 5-
HT1A receptors in the cortico-limbic regions do not desensitize or are downregulated in the 
process. Thus, the net effect is increased serotonin release over time (Gray et al., 2013). The 
hippocampus receives a high density of 5-HT innervation fibers from the raphe nucleus; thus, 5-
HT mediated neurotransmission increases neurogenesis in the hippocampus. Furthermore, 
specific 5-HT receptor subtypes such as 5-HT4 cause mature granule cells in the dentate gyrus to 
curb calbindin (Ca2+ binding protein) expression and begin to express characteristics of immature 
granule cells (Mahar et al., 2014).  
Negative Neuroplasticity in the Amygdala, VTA, and NAc 
The increase in BDNF promoting neurogenesis in the hippocampus and PFC also 
promotes neurogenesis in the amygdala, Ventral Tegmental Area (VTA), and Nucleus 
Accumbens (NAc) (Liu et al., 2017).  The increase in neurogenesis in the amygdala exasperates 




individuals with depression, CBT can help counter the amygdala's elevated activation if 
antidepressants alone are not sufficient (Arnau-Soler et al., 2016).  
The increase in BDNF does promote neurogenesis, but the effects are structure-dependent 
(Hayley et al., 2013). For example, the increased expression of BDNF in the amygdala, VTA, 
and NAc promotes neurogenesis, dendritic arborization, and synaptogenesis, but the effects are 
"negative neuroplasticity." Increased plasticity in the amygdaloid nuclei increases susceptibility 
to depression by augmenting the fear response. Although BDNF in the amygdala is a requisite 
for fear learning, excess enhancement of the fear response can promote pathology. This 
phenomenon is observed in individuals with depression in remission yet display heightened 
arousal and vigilance; even benign stressors could trigger a possible relapse if not managed 
immediately (Hayley et al. 2013). The importance and effects of combining pharmacotherapy 
with psychotherapy (CBT) can demonstrate its value in minimizing potential relapse and 
exhibiting synergistic effects (discussed in subsequent sections).  
PART III 
Neuroplasticity and Cognitive Behavior Therapy (CBT) 
As mentioned earlier in this review, neuroplasticity is the brain's ability to adapt and 
change by constant remodeling of synaptic connections and neurogenesis. Long-term 
potentiation and synaptic plasticity that are strengthened by repetitive firing are the basis for 
learning and memory. Based on Hebbian theory, “neurons that fire together, wire together” and 
“neurons that fire apart, wire apart” (Keysers et al., 2014). Furthermore, studies have shown that 
learning in concert with new interneuron connections leads to neurogenesis (Gould et al., 1999). 
The greater the redundancy in a specific behavior, the greater the anatomical and functional 




depends on the duration, timing, and intensity of the stimuli (Gunnar et al., 2006). Studies 
(Månsson et al., 2016) have shown that fear and anxiety increase the recruitment of neurons in 
the amygdala and the neuronal response to anxious behavior. A study (Månsson et al., 2016) 
displayed increased dendritic spine density after fear conditioning. Yet, negative neuroplasticity 
was reversed during fear extinction (Månsson et al., 2016). 
Cognitive behavior therapy (CBT) is fundamentally rooted in two ideologies: (a) that all 
behavior, adaptative or maladaptive, is learned; (b) cognitive distortions and faulty thinking give 
rise to psychological disorders. CBT theorists postulate that learning exists on an ever-changing 
continuum and that dysfunctional behavior that has been learned can be unlearned and replaced 
with functional behavior. CBT is a psychotherapeutic treatment that challenges and modifies 
beliefs, feelings, and behaviors (Corey, 2016). The underlying logic in CBT is that experience-
dependent learning follows the principles of neuroplasticity. Since CBT is a learning-based 
therapy, then it is logically sound to infer the effects of CBT should follow principles of 
neuroplasticity (Kleim & Jones, 2008). Therefore, faulty thinking or cognitive distortions that 
have been learned, accordingly, can be unlearned.  
CBT utilizes top-down processing (slow, explicit) that is more calculated than bottom-up 
processing (fast, implicit) (Clark & Beck, 2010). Top-down processing is performed by the 
orbitofrontal cortex (OFC), ventromedial PFC (vmPFC), and anterior cingulate cortex (ACC), 
among other subcortical regions and cortex regions that are involved in the regulation of 
emotions. For example, cognitive restructuring is a CBT technique used to replace faulty 
thinking with rational thinking, resulting in an appropriate emotional response that curtails 
negative emotions (Ochsner & Gross, 2007). The regulation of emotions positively results in 




axis. In turn, it results in positive neuroplasticity and a healthier mental state (Carlson et al., 
2007).  
CBT utilizes various techniques that educate an individual on the appraisal component of 
cognition by proactively assessing and evaluating thoughts and emotions in order to minimize 
faulty thinking. CBT teaches an individual to view thoughts and emotions with a filter that 
compartmentalizes thoughts and emotions as short-term, transient mental events (Shimamura, 
2000). This process allows an individual to consciously and proactively process thoughts, 
emotions, and behaviors (Shimamura, 2000). The result is the ability to determine and process 
thoughts, emotions, and behaviors that are beneficial, rather than automatically reacting to them 
(Chambers et al., 2009). 
Metacognition 
Metacognition is defined as "the monitoring and control of cognitive processing" 
(Shimamura, 2008).  The continuous appraisal of incoming stimuli and the respective 
accompanying emotions (adaptive or maladaptive) create the exhibited behavior and promote 
negative neuroplasticity and ultimately pathology. Metacognition is mediated by midfrontal 
brain regions, predominately PFC (extensive top-down control) (Shimamura, 2008). CBT 
addresses the metacognitive level and incorporates techniques such as mindfulness and other 
metacognitive therapies (Chambers et al., 2009).  
PART IV 
Antidepressants and CBT 
A poly-treatment approach has been shown to be efficacious in treating depression 
(Hayley et al., 2013). As mentioned in the background section, both antidepressants and CBT are 




Antidepressants' effects (Uscinska et al., 2019) consist of a "bottom-up" approach; in 
comparison, CBT's effects consist of a "top-down" approach.  The "bottom-up" approach is in 
reference to a two-step process entailing an incoming stimulus (implicit) that is processed by the 
limbic system before reaching the cortical regions. The "top-down" approach is a three-step 
process entailing an incoming stimulus, cognition of the stimulus, and an emotional response to 
the stimulus. An explanation for the differences in the approaches is that antidepressants 
predominantly act through the serotonergic system by modulating dorsal raphe nuclei (DRN) and 
its projections via serotonergic pathways in the subcortical and cortical regions (hippocampus, 
PFC, amygdala, basal ganglia) utilized in emotional processing (Godlewska et al., 2020). 
Conversely, CBT strengthens the frontal cortex regions (mPFC and anterior cingulate cortex 
[ACC]) by reducing negative bias, in turn improving emotional regulation (Hayley et al., 2103). 
The pregenual anterior cingulate cortex (pgACC) plays an important role in emotional and 
cognitive processing due to its central anatomical location in the neurocircuitry involved in top-
down processing (Godlewska et al., 2020). More broadly, antidepressants (pharmacotherapy) 
decrease limbic hyperactivity, and CBT (psychotherapy) increases emotional regulation. The 
goal is to strive for a healthy mental state where the brain structures can maintain a dynamic 
equilibrium where information that is processed by the amygdala, VTA, and NAc is regulated by 
cortical structures (PFC) in regulating emotions.   
CBT targets cognitive processes implicated in promoting negative schemata and negative 
bias (top-down effect) (Godlewska et al., 2020). In contrast, antidepressants target the brain 
structures (limbic system) involved in the formation of negative schemata and negative bias 
(bottom-up effect) (Godlewska et al., 2020). A study by Goldapple et al. (2004) observed lower 




With that said, this is a simplistic explanation of the complex inner workings of the brain. Both, 
antidepressants (pharmacotherapy) and CBT (psychotherapy) can have top-down and bottom-up 
effects, as the neurocircuitry and pathways in the brain can have overlapping effects (Godlewska 
et al., 2020).  
The combination of antidepressant and CBT have shown to result in synergistic effects 
(Godlewska et al., 2020). Antidepressants, utilizing the bottom-up process, modulate monoamine 
neurotransmission and begin improving mood by inducing positive neuroplasticity, but this takes 
time (~2 weeks). During this time, for best results, psychotherapy is recommended, which can 
immediately improve cognition, resulting in greater emotional regulation that is less taxing on 
the limbic system. Furthermore, studies have shown that an individual's environment has a 
tremendous influence on pharmacotherapy's efficacy. Thus, it is paramount that individuals 
beginning an antidepressant regimen be cognizant of how their environment can affect the 
antidepressant's efficacy (Godlewska et al., 2020). It is also important to note that without 
modified changes in top-down regulation via LTP, it will be challenging to induct new 












RECOMMENDATIONS FOR FUTURE STUDIES 
 
Future studies can provide evidence to support the correlation between the pathogenesis 
and the neuroplasticity of depression through several avenues: (a) continued research of how 
genetics influence the stress response, how genetics impact neuroplasticity in depression, and 
how genetics influence treatment efficacy; (b) a deeper understanding of the molecular 
mechanisms, such as intracellular signaling cascades involved in neuroplasticity of depression; 
and specific neurotransmitter receptor targets involved in the signaling cascades impacting 
antidepressant efficacy and future antidepressant development (Liu et al., 2017); and (c) a deeper 
understanding of antidepressants’ bottom-up treatment approach compared to psychotherapy’s 
top-down treatment approach.  
Currently, the combination of antidepressants and CBT is the preferred treatment method 
for the greatest efficacy. Advances in the technology for diagnosis and treatment of depression 
have enabled practitioners to personalize treatments for patients. Precision medicine considers 
clinical data and individual biomarkers, such as genetics, protein expression, neuroimaging, 
neurocognitive performance, personality, among other characteristics, to customize an 
individual’s treatment plan (Li et al., 2021). Therefore, precision medicine can serve as a 
pharmacogenetic guidance approach for depression, increasing the response rate and remission 
rate of antidepressants and psychotherapy (Li et al., 2021). Precision medicine for depression is a 
newer approach requiring further studies to better optimize its effectiveness as a treatment 
approach (Li et al., 2021). Finally, depression is a heterogeneous disorder, and with insufficient 
knowledge of its etiology and pathophysiology, the disorder’s complexity undermines the ability 
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